Healthcare >> CEO Interviews >> November 15, 2010
ROBERT BROOKE is the CEO and Chairman of Genesis Biopharma, Inc. He is also the Founder and President of Percipio Biosciences, a research diagnostics company that manufactures and distributes worldwide products related to oxidative stress research. From 2004 to 2008, Mr. Brooke was an Analyst with Bristol Capital Advisors, LLC, and an Investment Manager at Bristol Investment Fund, Ltd. During this period, he helped finance more than 60 public health care and life science companies, and Bristol was listed by The PIPEs Report as the most active investor in private placements by public biotechnology companies. Mr. Brooke is currently a member of the Los Angeles Gerontology Research Group. He earned a B.S. in electrical engineering from the Georgia Institute of Technology in 2003 and a M.S. in biomedical engineering from the University of California, Los Angeles, in 2005. Profile
TWST: Would you give us a broad overview of Genesis Biopharma and a history of the company?
Mr. Brooke: Genesis Biopharma (GNBP) is developing targeted cancer therapy for the treatment of aggressive
